RedHill sells Talicia to Apotex for $18M upfront, up to $53M total
What's the deal? RedHill Biopharma has divested its Talicia business to a subsidiary of Apotex Health CorpDealroom has a profile for this one. Try Dealroom → for $18 million in cash upfront, plus up to $35 million in additional payments tied to worldwide net sales milestones. RedHill, a specialty biopharmaceutical company, announced the transaction on August 31, 2026. In return, Apotex receives RedHill's 70% interest in Talicia, a treatment targeting H. pylori infection.
Why now? The sale consolidates full ownership of Talicia under Apotex. Apotex previously acquired Cumberland Pharmaceuticals'Dealroom has a profile for this one. Try Dealroom → US branded business, which included Cumberland's 30% stake in the product.
What's the endgame? RedHill says the deal converts its 70% Talicia stake into immediate capital and stronger liquidity. The company plans to use the proceeds to expand its gastrointestinal commercial franchise, including new FDA-approved product opportunities, and accelerate its path toward operational profitability.
What they're saying: "This transaction is a pivotal milestone for RedHill," said chief executive officer Dror Ben-Asher. He added that Apotex is "the right home to grow Talicia globally."
The signal: The divestment marks a deliberate repositioning: rather than defending a single asset held under shared ownership, RedHill is trading it for cash to fund larger, higher-value products. It reflects how smaller biopharma firms are streamlining portfolios to reach profitability faster.
Image credit: ccPixs.com
